eHealth-based Bavarian Alternative Detection of Atrial Fibrillation: A Randomized Controlled Trial (eBRAVE-AF)
Not Applicable
- Conditions
- Atrial Fibrillation
- Registration Number
- NCT04250220
- Lead Sponsor
- LMU Klinikum
- Brief Summary
Atrial fibrillation (AF) is the most common arrhythmia in western countries and causes of up to one quarter of ischemic strokes. The randomized eHealth-based Bavarian Alternative Detection of Atrial Fibrillation study (eBRAVE-AF) tests the efficacy of an e-health based strategy for the detection of AF. The e-health-based strategy consists of a smartphone-based photophlethysmographic (PPG) screening and an ECG-based validation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 4400
Inclusion Criteria
- policy holders of a large health insurance company
- age ≥50 years
- CHA2DS2-VASc ≥1 (females ≥2)
Exclusion Criteria
- atrial fibrillation
- oral anticoagulation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Number of participants with newly diagnosed atrial fibrillation within six months with prescription of oral anticoagulation 6 months
- Secondary Outcome Measures
Name Time Method Number of participants with thromboembolic events 6 months Number of participants with newly diagnosed atrial fibrillation 6 months Number of participants with stroke 6 months Number of participants with newly prescribed oral anticoagulation 6 months
Trial Locations
- Locations (1)
Klinikum der Universität München
🇩🇪München, Germany
Klinikum der Universität München🇩🇪München, Germany